Tapewire

Nasdaq · USD

ANIX

Anixa Biosciences Inc

Export transactions ↓
Tapewire entity
6698
SEC CIK
0000715446
Parsed reports
211

Last 12 months

Inside the activity.

18 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202610
Feb 202600
Mar 202600
Apr 202600
May 202600
Jun 202620
Jul 202680
Aug 202600
Sep 202670
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
September 30, 2026 Filed Sep 30, 2026 14:25 UTC
Catelani MichaelPresident, COO, & CFO
PurchaseCommon Stock 5,500 $2.84 $15,620.00
Disclosure

SEC source: 0001493152-26-045053 · ownership.xml · nonDerivative · entry 1

Catelani Michael · CIK 0001689394 · President, COO, & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Read SEC document
September 24, 2026 Filed Sep 28, 2026 12:45 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 7,000 $2.78 $19,460.00
Disclosure

SEC source: 0001493152-26-044458 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 672,000

Read SEC document
September 24, 2026 Filed Sep 28, 2026 12:30 UTC PurchaseCommon Stock 5,000 $2.76 $13,800.00
Disclosure

SEC source: 0001493152-26-044457 · ownership.xml · nonDerivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,572

Read SEC document
September 23, 2026 Filed Sep 25, 2026 12:39 UTC PurchaseCommon Stock 49,036 $2.69 $131,906.84
Disclosure

SEC source: 0001493152-26-044250 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,046,003

Read SEC document
September 10, 2026 Filed Sep 14, 2026 13:45 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 3,000 $2.75 $8,250.00
Disclosure

SEC source: 0001493152-26-042512 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 665,000

Read SEC document
September 10, 2026 Filed Sep 14, 2026 13:15 UTC PurchaseCommon Stock 10,000 $2.73 $27,300.00
Disclosure

SEC source: 0001493152-26-042502 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 996,967

Read SEC document
September 10, 2026 Filed Sep 11, 2026 12:00 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 5,000 $2.76 $13,800.00
Disclosure

SEC source: 0001493152-26-042302 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 662,000

Read SEC document
July 31, 2026 Filed Aug 3, 2026 08:45 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 5,000 $3.47 $17,350.00
Disclosure

SEC source: 0001493152-26-035751 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 657,000

Read SEC document
July 27, 2026 Filed Jul 27, 2026 15:25 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 3,188 $3.37 $10,743.56
Disclosure

SEC source: 0001493152-26-034772 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 647,000

Read SEC document
July 27, 2026 Filed Jul 28, 2026 10:20 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 5,000 $3.44 $17,200.00
Disclosure

SEC source: 0001493152-26-034952 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 652,000

Read SEC document
July 27, 2026 Filed Jul 29, 2026 09:14 UTC Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 6,000 $0.00 Strike: $3.13 $0.00
Disclosure

SEC source: 0001493152-26-035122 · ownership.xml · derivative · entry 3

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,000 shares

Expires 2026-08-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Right-To-Buy, pursuant to a stock option grant dated August 23, 2013.

Read SEC document
July 27, 2026 Filed Jul 29, 2026 09:14 UTC Tax withholdingCommon Stock 5,428 $3.46 $18,780.88
Disclosure

SEC source: 0001493152-26-035122 · ownership.xml · nonDerivative · entry 2

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,572

F1 · kind: The reporting person exercised the stock options at this time due to their expiration on August 23, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to cover the exercise price of the stock options.

Read SEC document
July 27, 2026 Filed Jul 29, 2026 09:14 UTC Exercise / conversionCommon Stock 6,000 $3.13 $18,780.00
Disclosure

SEC source: 0001493152-26-035122 · ownership.xml · nonDerivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 24, 2026 Filed Jul 27, 2026 09:00 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 3,000 $3.73 $11,190.00
Disclosure

SEC source: 0001493152-26-034723 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 643,812

Read SEC document
July 20, 2026 Filed Jul 20, 2026 18:19 UTC PurchaseCommon Stock 12,000 $3.47 $41,640.00
Disclosure

SEC source: 0001493152-26-033949 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 986,967

Read SEC document
July 20, 2026 Filed Jul 21, 2026 10:23 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 5,000 $3.46 $17,300.00
Disclosure

SEC source: 0001493152-26-034027 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 640,812

Read SEC document
July 15, 2026 Filed Jul 16, 2026 09:00 UTC PurchaseCommon Stock 2,797 $3.28 $9,174.16
Disclosure

SEC source: 0001493152-26-033461 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 974,967

Read SEC document
July 10, 2026 Filed Jul 13, 2026 08:59 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 5,000 $3.04 $15,200.00
Disclosure

SEC source: 0001493152-26-032961 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 635,812

Read SEC document
June 16, 2026 Filed Jun 17, 2026 11:21 UTC PurchaseCommon Stock 2,836 $2.64 $7,487.04
Disclosure

SEC source: 0001493152-26-029030 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 972,170

Read SEC document
June 12, 2026 Filed Jun 16, 2026 09:00 UTC
KUMAR AMITDirector · Chief Executive Officer
PurchaseCommon Stock 21,000 $2.50 $52,500.00
Disclosure

SEC source: 0001493152-26-028827 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 630,812

Read SEC document
January 28, 2026 Filed Jan 29, 2026 08:58 UTC PurchaseCommon Stock 10,000 $3.04 $30,400.00
Disclosure

SEC source: 0001493152-26-004148 · ownership.xml · nonDerivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,000

Read SEC document
January 05, 2026 Filed Jan 6, 2026 19:44 UTC GrantEmployee Stock Option · Derivative 25,000 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001493152-26-000689 · ownership.xml · derivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-01-05

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 19:42 UTC
KUMAR AMITDirector · Chief Executive Officer
GrantEmployee Stock Option · Derivative 350,000 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001493152-26-000688 · ownership.xml · derivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2036-01-05

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 19:41 UTC GrantEmployee Stock Option · Derivative 25,000 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001493152-26-000687 · ownership.xml · derivative · entry 1

Gottschalk Emily · CIK 0001791108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-01-05

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 19:41 UTC
Catelani MichaelPresident, COO & CFO
GrantEmployee Stock Option · Derivative 175,000 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001493152-26-000686 · ownership.xml · derivative · entry 1

Catelani Michael · CIK 0001689394 · President, COO & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 175,000

Underlying: Common Stock · 175,000 shares

Expires 2036-01-05

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2026.

Read SEC document
January 05, 2026 Filed Jan 6, 2026 19:40 UTC GrantEmployee Stock Option · Derivative 25,000 $0.00 Strike: $3.18 $0.00
Disclosure

SEC source: 0001493152-26-000685 · ownership.xml · derivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2036-01-05

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2026.

Read SEC document
December 15, 2025 Filed Dec 16, 2025 08:56 UTC Exercise / conversionEmployee Stock Option · Derivative 16,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001493152-25-027904 · ownership.xml · derivative · entry 2

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2026-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Right-To-Buy, pursuant to a stock option grant dated February 18, 2016.

Read SEC document
December 15, 2025 Filed Dec 16, 2025 08:56 UTC Exercise / conversionCommon Stock 16,000 $2.92 $46,720.00
Disclosure

SEC source: 0001493152-25-027904 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 969,334

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
October 30, 2025 Filed Oct 31, 2025 09:13 UTC
KUMAR AMITChief Executive Officer
Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative 200,000 $0.00 Strike: $2.92 $0.00
Disclosure

SEC source: 0001493152-25-020322 · ownership.xml · derivative · entry 3

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 200,000 shares

Expires 2026-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · security: Right-To-Buy, pursuant to a stock option grant dated February 18, 2016.

F3 · derivative.exercise_date: The option vested in 36 consecutive monthly installments beginning on March 31, 2016.

Read SEC document
October 30, 2025 Filed Oct 31, 2025 09:13 UTC
KUMAR AMITChief Executive Officer
Tax withholdingCommon Stock 169,439 $4.06 $687,922.34
Disclosure

SEC source: 0001493152-25-020322 · ownership.xml · nonDerivative · entry 2

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 610,486

F1 · kind: The reporting person exercised the stock options at this time due to their upcoming expiration on February 18, 2026. The disposal of shares reported herein represents shares withheld by Anixa Biosciences, Inc. (the "registrant") to (i) cover the exercise price of the stock options and (ii) satisfy tax withholding obligations in connection with the exercise of the stock options. Dr. Kumar did not sell any shares in connection with the exercise of the options.

Read SEC document
October 30, 2025 Filed Oct 31, 2025 09:13 UTC
KUMAR AMITChief Executive Officer
Exercise / conversionCommon Stock 200,000 $2.92 $584,000.00
Disclosure

SEC source: 0001493152-25-020322 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 779,925

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 31, 2025 Filed Aug 4, 2025 09:00 UTC PurchaseCommon Stock 10,000 $3.08 $30,800.00
Disclosure

SEC source: 0001641172-25-022000 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 953,334

Read SEC document
July 30, 2025 Filed Jul 31, 2025 09:00 UTC
KUMAR AMITChief Executive Officer
PurchaseCommon Stock 5,000 $3.16 $15,800.00
Disclosure

SEC source: 0001641172-25-021679 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 579,925

Read SEC document
July 18, 2025 Filed Jul 21, 2025 08:30 UTC PurchaseCommon Stock 5,000 $3.39 $16,950.00
Disclosure

SEC source: 0001641172-25-020362 · ownership.xml · nonDerivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Read SEC document
July 11, 2025 Filed Jul 14, 2025 08:40 UTC
KUMAR AMITChief Executive Officer
PurchaseCommon Stock 5,000 $3.15 $15,750.00
Disclosure

SEC source: 0001641172-25-018898 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 574,925

Read SEC document
July 11, 2025 Filed Jul 15, 2025 06:03 UTC PurchaseCommon Stock 10,000 $3.14 $31,400.00
Disclosure

SEC source: 0001641172-25-019587 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 943,334

Read SEC document
June 04, 2025 Filed Jun 5, 2025 09:11 UTC
KUMAR AMITChief Executive Officer
PurchaseCommon Stock 10,000 $2.85 $28,500.00
Disclosure

SEC source: 0001641172-25-013724 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 569,925

Read SEC document
January 28, 2025 Filed Jan 29, 2025 10:06 UTC PurchaseCommon Stock 5,000 $2.82 $14,100.00
Disclosure

SEC source: 0001493152-25-004108 · ownership.xml · nonDerivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Read SEC document
January 24, 2025 Filed Jan 27, 2025 09:14 UTC PurchaseCommon Stock 1,000 $3.00 $3,000.00
Disclosure

SEC source: 0001493152-25-003733 · ownership.xml · nonDerivative · entry 2

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 933,334

Read SEC document
January 23, 2025 Filed Jan 27, 2025 09:14 UTC PurchaseCommon Stock 2,000 $2.91 $5,820.00
Disclosure

SEC source: 0001493152-25-003733 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 932,334

Read SEC document
January 22, 2025 Filed Jan 23, 2025 09:11 UTC PurchaseCommon Stock 2,000 $3.01 $6,020.00
Disclosure

SEC source: 0001493152-25-003330 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 930,334

Read SEC document
January 21, 2025 Filed Jan 22, 2025 09:13 UTC PurchaseCommon Stock 6,000 $2.59 $15,540.00
Disclosure

SEC source: 0001493152-25-003157 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 928,334

Read SEC document
January 17, 2025 Filed Jan 17, 2025 14:05 UTC PurchaseCommon Stock 10,000 $2.57 $25,700.00
Disclosure

SEC source: 0001493152-25-002717 · ownership.xml · nonDerivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 922,334

Read SEC document
January 15, 2025 Filed Jan 15, 2025 13:15 UTC
KUMAR AMITChief Executive Officer
PurchaseCommon Stock 43,000 $2.23 $95,890.00
Disclosure

SEC source: 0001493152-25-002321 · ownership.xml · nonDerivative · entry 1

KUMAR AMIT · CIK 0001191905 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 559,925

Read SEC document
January 15, 2025 Filed Jan 15, 2025 12:48 UTC
Catelani MichaelPresident, COO, & CFO
PurchaseCommon Stock 9,289 $2.15 $19,971.35
Disclosure

SEC source: 0001493152-25-002314 · ownership.xml · nonDerivative · entry 1

Catelani Michael · CIK 0001689394 · President, COO, & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,500

Read SEC document
January 02, 2025 Filed Jan 3, 2025 17:40 UTC GrantEmployee Stock Option · Derivative 25,000 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001493152-25-000317 · ownership.xml · derivative · entry 1

Titterton Lewis H jr · CIK 0001499254 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-01-02

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2025.

Read SEC document
January 02, 2025 Filed Jan 3, 2025 17:40 UTC
KUMAR AMITDirector · Chief Executive Officer
GrantEmployee Stock Option · Derivative 700,000 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001493152-25-000316 · ownership.xml · derivative · entry 1

KUMAR AMIT · CIK 0001191905 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 700,000

Underlying: Common Stock · 700,000 shares

Expires 2035-01-02

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2025.

Read SEC document
January 02, 2025 Filed Jan 3, 2025 17:40 UTC GrantEmployee Stock Option · Derivative 25,000 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001493152-25-000315 · ownership.xml · derivative · entry 1

Gottschalk Emily · CIK 0001791108 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-01-02

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2025.

Read SEC document
January 02, 2025 Filed Jan 3, 2025 17:40 UTC GrantEmployee Stock Option · Derivative 25,000 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001493152-25-000313 · ownership.xml · derivative · entry 1

Baskies Arnold M · CIK 0001683567 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2035-01-02

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in twelve (12) equal monthly installments beginning January 31, 2025.

Read SEC document
January 02, 2025 Filed Jan 3, 2025 17:40 UTC
Catelani MichaelPresident, COO & CFO
GrantEmployee Stock Option · Derivative 350,000 $0.00 Strike: $2.37 $0.00
Disclosure

SEC source: 0001493152-25-000314 · ownership.xml · derivative · entry 1

Catelani Michael · CIK 0001689394 · President, COO & CFO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 350,000 shares

Expires 2035-01-02

F1 · security: Right-To-Buy, granted under the Anixa Biosciences, Inc. 2018 Share Incentive Plan.

F2 · derivative.exercise_date: The options vest and become exercisable in thirty-six (36) equal monthly installments beginning January 31, 2025.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.